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Abstract
Background: Certain Human Papillomaviruses (HPVs) are the infectious agents involved in cervical cancer
development. Detection of HPVs DNA is part of the cervical cancer screening protocols and HPVs genotyping has
been proposed for its inclusion in these preventive programs. The aim of this study was to evaluate three novel
genotyping tests, namely Qiagen LQ, RH and PS, in clinical samples with and without abnormalities. For this, 305
cervical samples were processed and the results of the evaluated techniques were compared with those obtained
in the HPVs diagnostic process in our lab, by using HC2 and Linear Array (LA) technologies.
Results: The concordances and kappa statistics (k) for each technique compared with HC2 were 98.69% (k = 0.94)
for LQ, 98.03% (k = 0.91) for RH and 91.80% (k = 0.82) for PS. There was a very good agreement in HPVs type-
specific concordance for the most prevalent types HPV16 (kappa range = 0.83-0.90), HPV18 (k.r.= 0.74-0.80) and
HPV45 (k.r.= 0.82-0.90).
Conclusions: The three tests showed an overall good concordance for HPVs detection when compared with HR-
HC2 system. LQ and RH rendered lower detection rate for multiple infections than LA genotyping. However, our
understanding of the clinical significance of multiple HPVs infections is still incomplete and therefore the relevance
of the lower ability to detect multiple infections needs to be evaluated.
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Background
Human Papillomaviruses (HPVs) are among the most
common viruses identified in sexually active women all
around the world, and persistence of the HPVs infection
is a necessary step for the development of cervical can-
cer [1]. Cervical cancer is the second most common
cancer in women, with a yearly incidence of 15.8 per
100,000 (crude rate), causing more than 270,000 deaths
in 2008 [2]. Other diseases with clinical relevance are
also related to HPVs infection, such as genital warts or
intraepithelial lesions and cancer of the vulva, penis,
vagina and anus [3-5].
More than 150 different PVs infecting humans have
been described [6]. Initially, and on the basis of epide-
miological studies of prevalence in cervical lesions,
HPVs with genital tropism were classified either as Low
Risk (LR-HPVs) or High Risk (HR-HPVs) [7]. Onco-
genic types such as HPV16, 18, 31 and 45 are responsi-
ble for the vast majority of all cervical cancers
worldwide [8], and are also present in other genital
lesions (penile or vulvar carcinomas). On the other
hand, LR-HPVs, such as HPV6 or HPV11, are usually
described as non-oncogenic and are associated to benign
lesions such as genital warts, condylomas or low grade
genital carcinomas [9].
Because of the clinical and economical relevance of
the lesions caused by HPVs infections, screening pro-
grams for the early detection of cervical cancer have
been established [10,11]. These pathology-preventive
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incorporated more recently HPVs detection as a supple-
mentary test. However, since infection by different
HPVs implies differential risk for the development of
cervical cancer [7,12,8], it has been proposed that HPVs
genotyping should be implemented as part of the HPVs
testing for cervical cancer screening programs [13]. Sev-
eral commercial methods for HPVs detection have been
developed and tested [14] in an effort for obtaining
robust and easy-to-use technology. Among them, the
FDA-approved Hybrid Capture 2 test (HC2; Qiagen,
Gaithersburg, MD, USA) is the most used methodology
for clinical purposes. HC2 technology has been evalu-
ated in several clinical assays, with better results than
cytology regarding sensitivity for HPV-related cytological
abnormalities detection [15,16]. HC2 is a HR-HPV-spe-
cific test for the detection of 13 HPVs: namely HPV16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. This test
detects HR-HPV in clinical samples, but the readout
refers to the presence/absence of the tested viruses, and
therefore cannot distinguish between single and multiple
infections and cannot resolve the presence of multiple
HPVs in one sample [17].
HC2 has been proposed and used as a reference meth-
odology for clinical HPV detection [18]. However, no
technology has been considered as a “gold standard” for
HPV genotyping in clinical samples, so all new proposed
technologies need to be compared with previous results
for assessing its validity and capacity to detect HPVs.
One of the most used genotyping methods, as well in
research and as in clinical use, is the Linear Array (LA;
Roche Molecular Systems, Branchburg, NJ, USA). This
hybridization, strip-based technique allows to identify 37
different HPVs, [19] spanning HR-HPVs, LR-HPVs and
other HPVs with still unclear differential association to
malignancy. LA has been used in HPVs detection and
genotyping in large epidemiological studies [20,21], and
has been proposed as a valid methodology for clinical
detection of HPVs in paraffin-embedded samples
[22,23].
The present study was designed to compare the per-
formance of three new HPVs genotyping methods,
namely digene HPV Genotyping LQ Test, digene HPV
Genotyping RH Test and digene HPV Genotyping PS
Test, with previous data from our HPVs diagnostic lab.
Baseline data were obtained by means of HC2 and LA
in the context of screening activities.
Methods
Clinical specimens and HC2 screening
Since 2006, Catalonia (Spain) has a population-based
program for cervical cancer to regulate cervical cytology
frequency and to reincorporate women with poor
screening history into the normalized monitorization
track. HPVs DNA detection using HC2 was introduced
for this later group as an adjuvant of cytology. In the
context of this preventive program, HC2 is also indi-
cated in the atypical squamous cells of undetermined
significance (ASC-US) triage.
Four hundred (400) cervical samples were obtained in
a retrospective way from four different centers partici-
pating of this cervical cancer screening program: Uni-
versity Hospital of Girona, Hospital Consortium of Vic,
Bellvitge University Hospital and Hospital of Tortosa
Verge de la Cinta. The criteria for the selection of the
samples were established in the working protocol as fol-
low: 90% of HC2+ samples and 10% of HC2- samples.
With this criterion, the samples were randomly selected
from the tested population in the four participating
centers.
Patients included in this program were women attend-
ing regular gynecologic visit, aged >40 years old with no
cytology in the five previous years (27.2% of the sample
size); women with ASC-US diagnosis in cytology (63.6%);
women in a follow-up protocol after surgery or previous
HC2+ test 9.2%). The cytological diagnoses were classi-
fied according to the Bethesda System (Table 1). The
mean age of the involved patients was 37.3 years old
(range 17-82). The final sample size was n = 305 samples
that were finally analyzed with the five techniques, after
excluding samples due to technical issues (e.g. not
enough material or invalid samples for some of the
protocols). All patients’ data were anonymized and the
samples were identified with a numerical key.
The samples were collected in digene Specimen Trans-
port Medium (STM) and tested for HR-HPVs by HC2.
Briefly, the samples were denatured and then incubated
with RNA probes for the HPVs types detected by the
Table 1 HPV DNA results by HC2 at entry and
concomitant cervical cytology diagnosis.
N % N* %*
HPV - 35 8.75 35 11.48
NEGATIVE 35 8.75 35 11.48
HPV+ 365 91.25 270 88.52
ASC-US 261 65.25 182 59.67
HSIL 9 2.25 7 2.30
LSIL 9 2.25 9 2.95
NEGATIVE 35 8.75 33 10.80
MISSING 51 12.75 39 12.80
TOTAL 400 100,00 305 100.00
The first two columns show the data of all selected women. The last two
columns (marked as *) show the data of samples finally tested with all the
techniques.
“ASC-US": Atypical Squamous Cells of Undetermined Significance; “CIN":
Cervical Intraepithelial Neoplasia; “HSIL": High Grade Squamous Intraepithelial
Lesion; “LSIL": Low Grade Squamous Intraepithelial Lesion.
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bodies attached to the wells of the working plate and
the reaction is revealed with chemiluminescent signal.
This signal is measured in a microplate luminometer,
and quantified as Relative Luminescence Units (RLU)
for each tested sample. The result of the test is
expressed as RLU relative to the cut-off value of the
technique, RLU/CO (HR-HPV negative 0<RLU/
CO<0.99; HR-HPV positive RLU/CO≥1).
DNA isolation
The remaining material from the HC2 denaturation pro-
tocol was aliquoted in two subsamples. Each half was
used for DNA extraction with the purification system
proposed by the manufacturers of the different genotyp-
ing systems. For LA genotyping, DNA was extracted
with the AMPLICOR AmpliLute DNA Extraction Kit
(Roche, reference 03750540 190). For LQ and RH geno-
typing, DNA was extracted with the QIAamp MinElute
Virus Spin Kit (Qiagen, reference 57704). In both cases,
the extraction was performed manually, according to the
manufacturer’s instructions.
Genotyping
1. - Linear Array
The DNA was first amplified and genotyped with the
LA technology as part of a follow-up study. This metho-
dology can amplify 37 different HPVs: HPV6, 11, 16, 18,
26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, IS39
(HPV82 subtype), 83, 84, and CP6108 (HPV89 subtype)
(Table 2) using the degenerate PGMY5+/6+ PCR system
and obtaining biotin-labeled amplimers of 450 bp on
the L1 gene [24,19]. The PCR reaction also included an
additional primer pair targeting the human b-globin
gene, giving a 268 bp fragment as internal control. Gen-
otyping was performed in an automated system, Auto-
LiPA 48 (Tecan Austria GmbH, distributed by Innoge-
netics). The amplimers were denatured and transferred
to the typing tray containing the genotyping strips
coated with HPVs and b-globin probes. The reaction of
the amplimer and the probe appears as a colored line in
the strip. The result of each sample was compared with
the standard guide to evaluate the presence/absence of
the different HPVs.
2. - LQ Test
The digene LQ genotyping system is a bead-based
xMAP technology for the detection of 18 HR-HPVs:
HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 73 and 82 [25,26]. Briefly, the probes for HPV
DNA detection are linked to coloured micro-beads, one
colour per HPV genotype detected. The micro-beads are
scanned by a two-laser system, one of the lasers identi-
fying the bead and the other one detecting the pre-
sence/absence of the linked amplimer. An internal
control for the detection of b-globin amplimers is
included in the beads mix. The extracted DNA is ampli-
fied with the GP5+/6+ PCR system, generating biotiny-
lated 150 bp amplicons on the L1 gene. The biotinylated
amplimers were mixed with the micro-beads under con-
trolled conditions of temperature and shaking. A conju-
gate for the detection was then added to the mix and
the final dilution read in a plate using a LiquiChip 200
Workstation MDD (QIAGEN, Gaithersburg, USA). The
results were analyzed and presented with the Software
Package QIAplex MDD (QIAGEN, Gaithersburg, USA).
3. - RH Test
The RH Test is a system for the detection of 18 HR-
HPVs: HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, 73 and 82 [27,28]. The specific probes are
immobilized onto nitrocellulose strips, including one
probe for the detection of an internal control using
human b-globin amplicon. After amplification with GP5
+/6+ PCR, the products are added to the plate contain-
ing the strips. Under stringent conditions, the amplicons
hybridize with the probes and the result visualized by
adding a conjugate and a substrate, whose reaction with
the hybrids produces a colored band. The genotyping
was performed in an automated system, Auto-LiPA 48
(Tecan Austria GmbH, distributed by Innogenetics).
4. - PS Test
PS Test is a HC2-based genotyping system for the spe-
cific detection of the three most significant HPVs,
namely HPV16, 18 and 45, and conceived as a “sec-
ond-step” after performing HC2 and having obtained
HR-HPV positive results. The working protocol is
Table 2 HPV genotypes detected by the different techniques
TEST DETECTED GENOTYPES
HC2 HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68
LA HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, CP6108
RH HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82
LQ HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82
PS HPV16, 18, 45
HC2: Hybrid Capture 2 System; LA: Linear Array.
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three different sets of HPV-specific probes. Each of
these sets is a mix of 25-long oligonucleotides with
targets distributed throughout the full-length of the
corresponding viral genomes showing no cross-reactiv-
ity with LR-HPVs. Briefly, the samples are denatured
and incubated with the probes. RNA/DNA hybrids are
linked to specific probes (one genotype per well and
sample) and the chemiluminiscent signal of the reac-
tion is read and measured by a luminometer. In the
same way as HC2, positive and negative calibrators as
well as positive and negative controls for each probe
are included in the working plate and provide the
reference cut off values for calculation of the RLU/CO
final results.
Statistical Methods
HPVs detection rates were calculated for each techni-
que. For the comparison of the results, only HPVs geno-
types shared by the different assays were considered, i.e.
when probes for the detection of the genotype in the
samples are included in HC2/LA but not in other of the
analyzed tests, the sample isc o n s i d e ra sH P V sn e g a t i v e
for the test. For the analyses of single/multiple infec-
tions, only HPVs genotypes shared by the compared
techniques were included in the comparisons.
Percent of concordance (and 95% Confidence Intervals
(CI)), agreement in positives (CI 95%) and agreement in
negatives (CI 95%) for each technique were assessed tak-
ing as a reference the HC2 and LA results. Cohen’s
kappa statistic and McNemar’s p-value were calculated
for the comparison of each test with LA results, estab-
lished as reference value for this comparative study.
Kappa index indicates the strength of the concordance
between techniques (based on a Normal distribution)
and ranks from 0 to 1.00 (<0.20: Poor; 0.21-0.40: Weak;
0.41-0.60: Moderate; 0.61-0.80: Good; 0.81-1.00: Very
Good) [29]. Standard error for kappa is calculated by
the method described by Fleiss and coworkers 1969
[30]. McNemar’s p-value indicates whether the
discordant cases between LA and each technique are
randomly distributed (p-value<0.05).
Results
Comparison of HPVs detection and overall concordances:
HC2 vs LQ/RH/PS
According to HC2 results, 270 of the 305 samples
(88.5%) were positive for HR-HPVs. After LA analysis,
none of the samples showed LR-HPV single infection,
and all HC2-negative samples tested also negative for
LA, LQ, RH and PS. Thus, no cross-reactivity with LR-
HPV was detected in the analyses of the samples.
Among all the HPVs DNA-positive samples tested with
LA, HR-HPVs single and multiple HPVs infections were
detected in 44.8% and 55.2% of the cases, respectively.
For the comparison of HPV positivity and type-speci-
fic detection rates, only HPVs genotypes common to the
compared assays were considered. With this, HPV posi-
tivity for LQ was 86, 9%, for RH was 86, 2% and 29, 8%
for PS. LQ and RH techniques rendered lower frequen-
cies than LA for multiple infections, (Table 3).
When the three techniques (LQ, RH and PS) were
compared with HC2 for positivity, concordance was
high: 98.7% (kappa (k.)= 0.94) for LQ; 98.0% (k.0 . 9 1 )
for RH; and 91.8% (k. 0.81) for PS. The agreement of
any of the tested technique with HC2/LA, with regard
to positivity, ranged between 80.0% and 98.9%. PS was
the one with the lowest sensitivity, mainly due to its low
HPV16 detection rate in single infections. These concor-
dance values decreased when analyzing separately by
single and multiple infections (Table 4).
I no r d e rt oe v a l u a t eam o r ec linical approach to the
analyses, these were performed including only genotypes
detectable by HC2. With this, five possible HR-HPV
genotypes were excluded (HPV26, 53, 66, 73 and 82).
The only difference with respect to the full analysis was
found in multiple infections detection with LQ test.
Contrary to the observation with the 18 genotypes ana-
lysis, no statistically significant difference was found
when comparing LA detection of multiple infection with
Table 3 HPV positive samples, single and multiple infections per assay among the 305 samples included in the study.
HPV+ Single infections Multiple infections P
&
TEST (common genotypes)* N %** N %# N %#
HC2/LA vs. LQ or RH 267 87.54 152 56.93 115 43.07
LQ 265 86.89 173 65.28 92 34.72 0.048
RH 263 86.23 194 73.76 69 26.24 <0.01
HC2/LA vs. PS 110 36.07 101 91.82 9 8.18
PS 91 29.84 87 95.60 4 4.40 0.278
“*": Common genotypes for HC2/LA vs LQ or RH: HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82; Common genotypes for HC2/LA vs PS:
HPV16, 18, 45 “**": % among total of tested samples (n = 305); “#": % among positive samples; HC2: Hybrid Capture 2 System; LA: Linear Array;"&": p-value for the
comparison of the proportion of multiple infections between LA and LQ, RH and PS.
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with 13 genotypes = 0.329).
Comparison of HPV genotyping results: LA vs LQ/RH/PS
The previous results obtained with LA showed that
positives for each of the 37 detectable genotypes, except
HPV69 and HPV64, were found in at least one of the
samples. The viruses most frequently found were
HPV16, 31, 58, 51 and 56 were with the three genotyp-
ing methods (Table 5)
When comparing LA and LQ/RH, 169 samples
(55.4%) were totally concordant and only thirteen (4%)
were totally discordant. For the rest of the samples par-
tial concordance was detected: i.e. LA showed at least
one genotype not detected by LQ/RH. On the other
hand, LQ and RH tests detected a higher number of
infections than LA for some genotypes, such as HPV16,
18, 45, 56 and 82 for LQ; and HPV16, 18, 56 and 82 for
RH (Table 5). For the PS test, which includes only three
HPVs genotypes, 74 of the 94 genotyped samples were
totally concordant with LA results and 17 were totally
discordant. Most of the discordant samples (14/17) were
positive for three or more different HPVs genotypes by
LA. The exact kappa values and ranges for type-specific
concordance comparisons are shown in Table 5.
The main differences were found in the concordance
analyses. Although the concordances were good or very
good, the distribution of the discordant was non-ran-
dom for some genotypes, such as HPV16 for PS and
HPV51, 56, 58 and 59 for LQ and/or RH. Some other
HPVs types showed weak concordance and/or non-ran-
domly distributed discordant, namely HPV26, 52, 53
and 68 and 73 (Figure 1).
Discussion
In this study we compared the performance of three
new HPVs genotyping technologies, namely digene LQ,
RH and PS Genotyping Tests, with FDA-approved HC2
technique for HPVs positivity/negativity, and with LA
methodology for HPVs genotyping, using clinical sam-
ples with and without HPVs infection. Statistical ana-
lyses of the data showed very good concordance for
HPVs detection for all the techniques (range 91.8% -
98.7%), and the kappa indexes of the concordances for
the two most relevant HPVs in cervical cancer were
between 0.82-0.90 for HPV16 and 0.74-0.79 for HPV18.
HC2 is the most widely used technology for HPVs
detection [16,31] and has been proposed as a reference
for the comparison of new techniques [18]. It includes
probes for thirteen different HR-HPVs. The HC2 proto-
col performed in our lab cannot detect LR-HPVs, and
the results provide exclusively information on the pre-
sence/absence of HPVs DNA, without further genotyp-
ing ability.
The concordance in HPVs detection is above 90% for
all the compared techniques. In the case of agreement
in positives LQ and RH tests rendered values of 98.9%
and 98.1% respectively while PS test showed an 80.0%,
when compared with HC2. Regarding agreement in
negatives all LQ, RH and PS displayed values higher
than 97%.
The observed differences in the detection rates by
assay when compared with HC2 were not statistically
significant. Part of the variability could be explained by
technical and design issues. First, the study is based on
a retrospective design and the working protocols were
performed in samples previously obtained. These sam-
ples were initially tested for HC2 and LA and aliquots
of material, both DNA and denatured STM, were kept
frozen at -80°C. For PS test, the material used was the
denatured one remaining from the HC2 testing. A
decrease in the RLU/CO signal is expected after re-test-
ing the same sample two or more times with HC2 tech-
nology [32], this decrease being greater if the material
Table 4 Concordance values between LQ, RH and PS techniques for HPV DNA detection using HC2/LA as reference
values
ASSAY
NEGATIVE vs. POSITIVE LQ (N = 265+/40-) RH (N = 263+/42-) PS (N = 91/214-)
% concordance (95% CI) 98.69 (96.68-99.64) 98.03 (95.77-99.27) 91.80 (88.14-94.62)
Kappa index (95% CI) 0.94 (0.88-0.99) 0.91 (0.84-0.98) 0.81 (0.75-0.88)
Agreement among positives (95% CI) 98.88 (96.75-99.77) 98.13 (95.68-99.39) 80.00 (71.30-87.02)
Agreement among negatives (95% CI) 97.37 (86.19-99.93) 97.37 (86.19-99.93) 98.46 (95.57-99.68)
NEGATIVE vs. POSITIVE SINGLE vs. POSITIVE MULTIPLE LQ RH PS
% concordance 75.74 (70.53-80.44) 75.08 (69.83-79.84) 89.84 (85.88-92.99)
Kappa index (95% CI) 0.59 (0.50-0.67) 0.57 (0.48-0.66) 0.78 (0.71-0.85)
Agreement among positives single infection (95% CI) 82.89 (75.95-88.51) 89.47 (83.47-93.86) 78.22 (68.90-85.82)
Agreement among positives multiple infection (95% CI) 59.13 (49.57-68.21) 48.70 (39.27-58.19) 33.33 (7.48-70.07)
“CI": Confidence Interval; “% Concordance” and “Kappa index (95% CI)": referred to HC2 result.
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GENOTYPE LA vs. LQ/RH LQ RH LA vs. PS PS
(n) (n) kappa
(95% CI)
McNemar’s
p-value
(n) kappa (95% CI) McNemar’s
p-value
(n) (n) kappa
(95% CI)
McNemar’s
p-value
HPV 16 90 93 0.898
(0.845 - 0.952)
0.581 91 0.898
(0.844 - 0.952)
1.000 90 73 0.825
(0.753 - 0.896)
0.000
HPV 16 SI 36 51 0.720
(0.608 - 0.832)
0.001 60 0.658
(0.543 - 0.772)
0.000 81 69 0.806
(0.728 - 0.883)
0.017
HPV 16 MI 54 42 0.581
(0.455 - 0.707)
0.058 31 0.473
(0.335 - 0.611)
0.000 9 4 0.452
(0.114 - 0.790)
0.125
HPV 18 20 25 0.736
(0.588 - 0.885)
0.227 22 0.795
(0.658 - 0.933)
0.727 20 14 0.751
(0.586 - 0.916)
0.070
HPV 18 SI 5 8 0.607
(0.292 - 0.923)
0.375 9 0.562
(0.249 - 0.876)
0.219 13 12 0.708
(0.502 - 0.914)
1.000
HPV 18 MI 15 17 0.538
(0.324 - 0.752)
0.791 13 0.626
(0.412 - .840)
0.754 7 2 0.439
(0.035 - 0.842)
0.063
HPV 45 9 11 0.897
(0.754 - 1.000)
0.500 9 0.886
(0.728 - 1.000)
1.000 9 8 0.818
(0.617 - 1.000)
1.000
HPV45 SI 5 6 0.907
(0.727 - 1.000)
1.000 5 1.00
(1.000 - 1.000)
1.000 7 6 0.921
(0.768 - 1.000)
1.000
HPV 45 MI 4 5 0.662
(0.302 - 1.000)
1.000 4 0.747
(0.408 - 1.000)
1.000 2 2 0.497
(0.000 - 1.000)
1.000
HPV 31 41 39 0.885
(0.806 - 0.963)
0.727 36 0.837
(0.742 - 0.931)
0.227
HPV 58 36 26 0.821
(0.714 - 0.928)
0.020 23 0.757
(0.632 - 0.882)
0.000
HPV 51 34 28 0.785
(0.667 - 0.902)
0.146 21 0.702
(0.561 - 0.843)
0.001
HPV 52 33 21 0.474
(0.304 - 0.645)
0.029 21 0.515
(0.347 - 0.683)
0.023
HPV 66 28 27 0.820
(0.706 - 0.935)
1.000 23 0.808
(0.686 - 0.930)
0.180
HPV 53 28 11 0.486
(0.293 - 0.679)
0.000 8 0.421
(0.221 - 0.621
0.000
HPV 39 25 17 0.796
(0.659 - 0.933)
0.008 17 0.745
(0.594 - 0.896)
0.021
HPV 33 21 22 0.825
(0.698 - 0.952)
1.000 20 0.869
(0.756 - 0.982)
1.000
HPV 56 21 29 0.739
(0.599 - 0.880)
0.039 28 0.756
(0.618 - 0.894)
0.065
HPV 59 20 10 0.651
(0.452 - 0.851)
0.002 10 0.651
(0.452 - 0.851)
0.002
HPV 35 12 11 0.955
(0.866 - 1.000)
1.000 9 0.852
(0.688 - 1.000)
0.250
HPV 68 10 9 0.620
(0.360 - 0.879)
1.000 10 0.586
(0.326 - 0.847)
1.000
HPV 73 9 4 0.608
(0.295 - 0.922)
0.063 2 0.357
(0.000 - 0.717)
0.016
HPV 82 4 6 0.594
(0.231 - 0.956)
0.625 6 0.797
(0.522 - 1.000)
0.500
HPV 26 2 2 0.497
(0.000 - 1.000)
1.000 1 0.665
(0.048 - 1.000)
1.000
“n": Number of cases HPV type-specific positive; “CI": Confidence interval.
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PS tests are hybridization-based it may be arguable that
they may suffer from the same limitations, which could
explain the relative low detection rate of the PS test. No
other comparative study with PS test has been pub-
lished, neither prospective nor retrospective, and the
loss in performance should be further studied. For RH
and LQ tests, re-extracted DNA was amplified for geno-
typing. LQ and RH are PCR-based test so that even if
the quality and/or the amount of the DNA is not totally
preserved, the amplification protocol may still achieve
detection rates similar to those with HC2- based tests.
Second, regarding the technical part, two closely-
related issues should be considered for the PCR-based
tests. On the one hand, DNA quality and purity is a key
point in the PCR-based protocols [33] and different iso-
lation procedures may suit best different PCR amplifica-
tion systems. For PGMY09/11 and GP5+/6+
amplifications, DNA was extracted with silica filter-
based commercial kits, ensuring enough purity and
quality for downstream applications. On the other hand,
two different sets of primers were used and differential
assay sensitivity HPV type-specific cannot be excluded.
The PGMY9/11 primer set used in LA generates an
amplicon of 450 bp, which encompasses the 150 bp
amplicon generated with the GP5+/6+ primer set used
in LQ and RH tests. Longer amplimers are more sensi-
tive to DNA nicks and fragmentation. This could
explain in our case, the higher detection rate of HPV16,
18, 45, 56 and 82 in LQ or RH with respect to LA (3%
and 1% higher detection rates for HPV16 using LQ and
RH, respectively; 25% and 10% for HPV18). Finally,
simultaneous amplification of multiple targets using
degenerate primers implies that different HPVs DNA
templates compete with each other and with different
affinities for the primers. This competition can lead to
biases in the results, as has been previously described
for HPV16 [27]. In our study, all samples positive for
HPV16 and HPV18 with LQ and RH but that had tested
negative for both viruses with LA corresponded to mul-
tiple infections. We interpret therefore these differences
as arising from primers mismatch and from competition
between genotypes present in the sample [34].
The proportion of multiple infections detected with
LA is higher than with LQ or RH techniques, even after
correcting for the different number of genotypes
included in the determination (Table 3). Similar findings
on the power of LA to identify higher rates of multiple
infections as well as to detect a larger number of geno-
types in the multiple infections had been previously
Figure 1 Type specific concordance between LA and LQ, RH and PS techniques (N = 305). The genotyping results for each of the tested
techniques vs. LA are presented in a color-coded way. Concordances LA/LQ are presented in black, LA/RH in red and LA/PS in blue.
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Page 7 of 10reported [12]. The clinical relevance of this increased
ability to reveal multiple infections still needs to be clar-
ified, as it is also the case for the implications of multi-
ple infections in clinical prognosis. The LQ, RH and PS
tests have been developed for clinical settings with the
aim of identifying only medically relevant infections
[35]. For this purpose, their sensitivity cut-off values lay
a higher range than that of LA. As an example, in the
case of HPV 58 and HPV59, LA shows lower detection
levels for these genotypes than for the rest of detectable
genotypes (185 copies/mL and 53 copies/mL respec-
tively). The LQ cut-off value used was the one supplied
and recommended by the Luminex software (100 Med-
ian Fluorescence Intensity, MFI). Cut-off values as low
as 30 MFI have been demonstrated to be useful for
HPVs detection, with the trade-off of a concomitant
increase in HPVs detection rate [25].
Despite of the good concordances showed in our
study, some differences were found in the agreement of
the detection rates. Figure 1 shows the graphic represen-
tation of the Kappa value-McNemar’sp - v a l u er e l a t i o n
for each genotype when the techniques are compared.
Here we could see how HPV genotypes detected with
good concordance between techniques and randomly
distributed discordant appeared in the right side of the
graphic (e.g. HPV16, 33, 35 and 45). When moving to
lower values of Kappa and McNemar, we could find
genotypes in the “Weak concordance - Discordant not
random“ region of the graphic (e.g. HPV52, 53 and 73).
For HPV52 and 53, technical issues could explain these
mismatches. Thus, LA tends to overestimate the detec-
tion rate of HPV52 because of the cross-reactivity with
other probes in the stripe (e.g. HPV33, 35 and 58). In
our case, LA detected 33 HPV52 infections, while LQ
and RH systems detected 21 infections each. For
HPV53, false negativity has been reported when using
the GP primer set [36], as in our case (28 LA vs. 11 LQ
vs. 8 RH)
In technical terms, the tests are comparable according
to their requirements in sample and in working time.
The required sample amount for PCR-based protocols is
the same, 10 μL DNA. Furthermore, in the case of LQ
and RH, the same PCR product can be used for both
tests: LQ detection just needs 4 μL of the amplimer, and
RH requires 10 μL. On the other hand, a larger amount
of sample is needed for PS test, namely 3 × 75 μLp e r
sample. This can be a limitation for the process, as the
samples are supposed to be first analyzed by HC2 (75
μL per sample) and then genotyped by PS. If the proto-
col needs to be repeated, the remaining material may
not be enough.
Regarding working time, LQ system was the one offer-
ing the best ratio samples analyzed/time invested; up to
96 samples could be analyzed in a two hours protocol.
For the same amount of analyzed samples, LA and RH
tests needed to be performed three times, amounting up
to six hours. PS required the same time as HC2, but
only 28 samples could be analyzed per protocol, so
three different plates might be analyzed for obtaining
results of 96 samples.
In conclusion, LQ, RH and PS tests showed an overall
good concordance for HPVs detection when compared
with the FDA approved HR-HC2 system. The three
tests displayed type-specific differences with LA geno-
typing, with PS showing the highest discordance. LQ
and RH rendered lower detection rate for multiple
infections than LA genotyping. However, our under-
standing of the clinical significance of multiple HPVs
infections is still incomplete and therefore the relevance
of the lower ability to detect multiple infections needs
to be evaluated.
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